8-KMaterial Agreements

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Mar 18, 2005)

Filed March 18, 2005For Securities:VRTX

Summary

This Form 8-K filing from Vertex Pharmaceuticals (VRTX) on March 17, 2005, details changes to the compensation structure for its non-employee directors, effective March 14, 2005. The adjustments aim to ensure competitive compensation to attract and retain qualified individuals, acknowledging an increased workload. Key changes include a new annual retainer, meeting fees, and committee chair retainers, alongside equity awards in the form of stock options for new and existing directors.

Key Highlights

  • 1Vertex Pharmaceuticals is updating its compensation for non-employee directors to remain competitive and address increased responsibilities.
  • 2Effective March 14, 2005, new cash compensation includes an annual retainer of $25,000 for board service.
  • 3Additional cash compensation is provided for attending Board and committee meetings, with varying rates for in-person and conference call meetings.
  • 4Committee Chairs will receive additional annual retainers: $20,000 for Corporate Governance & Nominating, $15,000 for Audit, and $10,000 for Management Development & Compensation.
  • 5New non-employee directors will receive an initial grant of 20,000 stock options vesting over four years.
  • 6Existing non-employee directors receive an annual grant of 10,000 stock options, exercisable immediately, on June 1st of each year.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce and detail the updated compensation structure for Vertex Pharmaceuticals' non-employee directors, which became effective on March 14, 2005.

The new structure includes an annual retainer of $25,000, plus fees for attending Board and committee meetings. Committee Chairs also receive additional annual retainers based on their specific committee.

Non-employee directors will receive stock options. New directors get an initial grant of 20,000 options vesting over four years, while existing directors receive an annual grant of 10,000 options each year on June 1st.

The company is adjusting compensation to ensure it remains competitive to attract and retain qualified non-employee directors, acknowledging a perceived increase in their workload.